Roche Holding AG Share Price

Equities

ROG

CH0012032048

Pharmaceuticals

Market Closed - Swiss Exchange 16:30:02 17/05/2024 BST 5-day change 1st Jan Change
237.1 CHF +0.98% Intraday chart for Roche Holding AG +5.33% -3.03%

Financials

Sales 2024 * 60.06B 66.04B 5,204B Sales 2025 * 63.61B 69.95B 5,511B Capitalization 191B 210B 16,572B
Net income 2024 * 13.41B 14.75B 1,162B Net income 2025 * 14.87B 16.35B 1,288B EV / Sales 2024 * 3.41 x
Net Debt 2024 * 13.75B 15.12B 1,192B Net Debt 2025 * 7.73B 8.5B 670B EV / Sales 2025 * 3.13 x
P/E ratio 2024 *
13.8 x
P/E ratio 2025 *
12.6 x
Employees 103,605
Yield 2024 *
4.1%
Yield 2025 *
4.24%
Free-Float 88.91%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.98%
1 week+5.33%
Current month+7.48%
1 month+7.72%
3 months+3.90%
6 months-0.21%
Current year-3.03%
More quotes
1 week
221.70
Extreme 221.7
238.40
1 month
212.90
Extreme 212.9
238.40
Current year
212.90
Extreme 212.9
255.90
1 year
212.90
Extreme 212.9
293.55
3 years
212.90
Extreme 212.9
404.20
5 years
212.90
Extreme 212.9
404.20
10 years
206.35
Extreme 206.35
404.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 49 31/12/02
Chairman 57 31/12/07
Director of Finance/CFO 57 31/03/11
Members of the board TitleAgeSince
Director/Board Member 72 02/03/15
Director/Board Member 59 -
Director/Board Member 66 31/12/95
More insiders
Date Price Change Volume
17/05/24 237.1 +0.98% 1,769,703
16/05/24 234.8 +3.21% 2,567,675
15/05/24 227.5 +1.29% 1,385,260
14/05/24 224.6 -1.40% 1,601,641
13/05/24 227.8 +1.20% 1,268,808

Delayed Quote Swiss Exchange, May 17, 2024 at 04:30 pm

More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Calendar
22/05/2024 - Investor Day
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
237.1 CHF
Average target price
279.4 CHF
Spread / Average Target
+17.84%
Consensus